MK-0448, a specific Kv1.5 inhibitor safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans

Circulation: Arrhythmia and Electrophysiology

Volumn 5, Issue 6, 2012, Pages 1193-1201

  Pavri, Behzad B ^a   Greenberg, Howard E ^a   Kraft, Walter K ^a   Lazarus, Nicole ^b   Lynch, Joseph J ^b   Salata, Joseph J ^b   Bilodeau, Mark T ^b   Regan, Christopher P ^b   Stump, Gary ^b   Fan, Li ^b   Mehta, Anish ^b   Wagner, John A ^b   Gutstein, David E ^b   Bloomfield, Daniel ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Arrhythmia; Atrial fibrillation; Electrophysiology; Pharmacokinetics

Indexed keywords

MK 0448; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE IRRITATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; SINGLE DRUG DOSE; SINUS RHYTHM; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION;

ADULT; ANIMALS; ATRIAL FIBRILLATION; DELAYED RECTIFIER POTASSIUM CHANNELS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; HEART CONDUCTION SYSTEM; HEART FAILURE; HUMANS; KV1.5 POTASSIUM CHANNEL; MALE; POTASSIUM CHANNEL BLOCKERS; PYRIDINES; SINOATRIAL NODE; SULFONAMIDES; VAGUS NERVE;

EID: 84873803407     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.111.969782     Document Type: Article

References (29)

1. Vidaillet H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, Sharma P, Smith PN, Hayes J. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113:365-370.
2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-2925.
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359-364.
4. FusterV, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906.
5. Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs. 2004;64:2741-2762.
6. Singh SN, Patrick J, Patrick J. Antiarrhythmic Drugs. Curr Treat Options Cardiovasc Med. 2004;6:357-364.
7. Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993;270:2451-2455.
8. Burashnikov A, Antzelevitch C. New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol. 2009;14:290-300.
9. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73:1061-1076.
10. Regan CP, Kiss L, Stump GL, McIntyre CJ, Beshore DC, Liverton NJ, Dinsmore CJ, Lynch JJ Jr. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4- phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl- ethanol in dogs with underlying heart failure. J Pharmacol Exp Ther. 2008;324:322-330.
11. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, Terzic A. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet. 2006;15:2185-2191.
12. Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart Rhythm. 2008;5:1304-1309.
13. Wettwer E, Hála O, Christ T, Heubach JF, Dobrev D, Knaut M, Varró A, Ravens U. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation. 2004;110:2299-2306.
14. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5:1034-1049.
15. Regan CP, Stump GL, Wallace AA, Anderson KD, McIntyre CJ, Liverton NJ, Lynch JJ Jr. In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate. J Cardiovasc Pharmacol. 2007;49:236-245.
16. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696.
17. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-1513.
18. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-1794.
19. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126:476-486.
20. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
21. Ford JW, Milnes JT. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol. 2008;52:105-120.
22. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace. 2008;10:647-665.
23. Insulander P, Vallin H. Gender differences in electrophysiologic effects of mental stress and autonomic tone inhibition: a study in health individuals. J Cardiovasc Electrophysiol. 2005;16:59-63.
24. Korkushko OV, Shatilo VB, Plachinda YuI, Shatilo TV. Autonomic control of cardiac chronotropic function in man as a function of age: assessment by power spectral analysis of heart rate variability. J Auton Nerv Syst. 1991;32:191-198.
25. Hayano J, Sakakibara Y, Yamada A, Yamada M, Mukai S, Fujinami T, Yokoyama K, Watanabe Y, Takata K. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am J Cardiol. 1991;67:199-204.
26. Toska K, Eriksen M. Respiration-synchronous fluctuations in stroke volume, heart rate and arterial pressure in humans. J Physiol (Lond). 1993;472:501-512.
27. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325.
28. Takahashi Y, Jaïs P, Hocini M, Sanders P, Rotter M, Rostock T, Hsu LF, Sacher F, Clémenty J, Haïssaguerre M. Shortening of fibrillatory cycle length in the pulmonary vein during vagal excitation. J Am Coll Cardiol. 2006;47:774-780.
29. Katsouras G, Sakabe M, Comtois P, Maguy A, Burstein B, Guerra PG, Talajic M, Nattel S. Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm. 2009;6:1465-1472.